PureTech Health (LON:PRTC) Stock Price Up 14.2% - Here's What Happened

Key Points

• PureTech Health shares surged by 14.2%, reaching as high as GBX 123.80 ($1.67), with a trading volume of over 9 million shares, significantly higher than its average.
• The company has a market capitalization of £293.65 million and operates in the biopharma sector, focusing on developing medications for various health issues.
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's performance.

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price shot up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares changed hands during trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Trading Down 0.2%

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a market capitalization of £302.59 million, a PE ratio of 736.47 and a beta of 1.02. The company has a fifty day moving average of GBX 129.31 and a 200-day moving average of GBX 129.65.

Insider Buying and Selling

In other news, insider Bharatt Chowrira bought 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is currently owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.